Erkan Aydin

Erkan Aydin

Auto-generated profile, based on publicly available information

Erkan Aydin

Bağcılar Research and Training Hospital, Psychiatry Clinic

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2024 in Medeniyet Medical Journal
Verified
Journal Article
Open access
KAKadir Arslan
Kadir Arslan
GUGozde Ucuksarac
Gozde Ucuksarac
HAHale Cetin Arslan
Hale Cetin Arslan
EAErkan Aydin
Erkan Aydin
ASAyca Sultan Sahin
Ayca Sultan Sahin
This retrospective observational study aimed to investigate the effect of different doses of sugammadex used in reversing neuromuscular blockade in electroconvulsive therapy (ECT) procedures on patient recovery and hemodynamic measurements. Anesthesia induction was performed using propofol (1 mg/kg) and rocuronium (0.4 mg/kg). Patients were classified into group 2 (2 mg/kg) and group 3 (3 mg/kg) according to the dose of sugammadex used to reverse neuromuscular blockade. The patient's spontaneous breathing time, eye-opening time, time to comply with voluntary commands, time to reach Modified Aldrete score (MAS) 9, complications, and hemodynamic data were analyzed. In total, 314 ECT sessions were performed on 46 patients. The average age of the patients was 38.3±12.6 years, and 56.6% (n=26) were male. While the average number of ECTs applied to the patients was 6.8±2.8, the average seizure duration was 28.2±12.7 seconds. The most common diagnosis (32.7%) in patients who underwent ECT was bipolar disorder. The average time to recovery of spontaneous breathing, eyeopening time, time to comply with voluntary commands, and time to reach MAS 9 were found to be significantly lower in group 3 (p<0.001, p<0.001, p0.05). Sugammadex used at a dose of 3 mg/kg in ECT procedures significantly reduces recovery times compared with 2 mg/kg. However, both doses can be safely and cost-effectively used to reverse the neuromuscular blockade provided by 0.4 mg/kg rocuronium.

30 September 2025 in BMC Cancer
Verified
Journal Article
Open access
SASabin Goktas Aydin
Sabin Goktas Aydin
BOBahar Ozguzel
Bahar Ozguzel
BBBahar Bayramova
Bahar Bayramova
EBErsin Budak
Ersin Budak
EAErkan Aydin
Erkan Aydin
FAFatma Bengu Aydin
Fatma Bengu Aydin
Cognitive impairment is a recognized challenge for cancer survivors, often linked to chemotherapy’s neurotoxic effects. In colorectal cancer (CRC), this impact remains less understood despite emerging evidence. This study aims to evaluate cognitive flexibility, memory, and attention in colorectal cancer patients compared to healthy controls. This prospective study assessed cognitive function in 58 colorectal cancer patients and 32 healthy, age- and education-matched controls. Cognitive testing was conducted within four weeks of chemotherapy completion. Exclusion criteria included pre-existing cognitive issues, brain metastases, and medications affecting cognition. Tests included Sensory Perception, Total Learning Score, Long-Term Memory Score, Stroop Test, and Trail Making Test. The median age of the cancer group was 56.5 years (range: 29–70), while the median age for the control group was 52 years (range: 28–66). Cancer patients demonstrated significantly poorer performance across several cognitive domains. Total Learning Scores were notably lower in the cancer group (mean rank 40.23 vs. 55.05, p = 0.01), indicating reduced learning capacity. Trail Making Test A and B times were significantly longer for cancer patients (p = 0.004), reflecting deficits in visual attention and cognitive flexibility. Stroop Test performance also showed significant delays across all time points (p = 0.002 to p = 0.02), suggesting impaired processing speed and executive control. Subgroup analysis of stage IV patients revealed even greater deficits, with significantly lower Total Learning Scores (p = 0.001) and slower Trail Making Test completion times (p < 0.001). No significant differences emerged in sensory perception or long-term memory. The research revealed significant cognitive difficulties in colorectal cancer patients after undergoing chemotherapy, especially in areas such as learning, attention, and executive function, with the most severe impairments observed in those with stage IV cancer.

18 August 2026 in Annals of Medicine
Verified
Journal Article
Open access
MYMenekşe Sıla Yazar
Menekşe Sıla Yazar
EYEren Yıldızhan
Eren Yıldızhan
KMKumru Şenyaşar Meterelliyoz
Kumru Şenyaşar Meterelliyoz
SASelim Arpacıoğlu
Selim Arpacıoğlu
EAErkan Aydın
Erkan Aydın
Community-based services have increasingly shifted from institutional treatment for those with severe mental illness over the past several decades. Beyond influencing treatment modalities, this tra...